References
- Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017 [Published 2017 Apr 24];8:469.
- Granatowicz A, Piatek CI, Moschiano E, et al. An overview and update of chronic myeloid, leukemia for primary care physicians. Korean J Fam Med. 2015;36:197–202.
- Thompson PA, Kantarjian H, Cortes JE. Diagnosis and treatment of chronic myeloid, leukemia (CML) in 2015. Mayo Clin Proc. 2015;90(10):1440–1454.
- Shu C, Liao K, Chen Y, et al. The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. Sci Rep. 2019 [Published 2019 Aug 15];9(1):11901.
- Senn L, Kovacsovics T, Tarr PE, et al. Peritoneal tuberculosis after imatinib therapy. Arch Intern Med. 2009;169:312–316.
- Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013;3:37–49.
- Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study. Medicine (Baltimore). 2017;96(28):e7482.
- Cao L, Greenblatt DJ, Kwara A. Inhibitory effects of selected antituberculosis drugs on common human hepatic cytochrome P450 and UDP-glucuronosyltransferase Enzymes. Drug Metab Dispos. 2017;45:1035–1043.
- Liu C-J, Hong Y-C, Teng CJ, et al. Risk and impact of tuberculosis in patients with chronic myeloid leukemia: a nationwide population-based study in Taiwan. Int J Cancer. 2015;136:1881–1887.
- Climent N, Plana M. Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral infection. Front Pharmacol. 2019;10:1232.
- Daniels JMA, Vonk-Noordegraaf A, Janssen JJ, et al. Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2009;33:670–672.
- Glaziou P, Sismanidis C, Floyd K, et al. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med. 2014;5(2):a017798.
- Khan FY, Dosa K, Fuad A, et al. W disseminated tuberculosis among adult patients admitted to hamad general hospital, Qatar: a five year hospital based study. Mycobact Dis. 2016;6:2.
- Bhuian TM, Rahman MM, Hoque MN, et al. Peritoneal tuberculosis in a patient with chronic myeloid leukemia and diabetes mellitus: a diagnostic dilemma. Mymensingh Med J. 2011;20:614–619.
- Törün T, Güngör G, Ozmen I, et al. Side effects associated with the treatment of multidrug resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:1373–1377.
- de Lima Corvino DF, Kosmin AR. Tuberculosis Screening. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 [cited 2020 Jun 11]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK448205/
- Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020. MMWR Recomm Rep. 2020;69:1–11.
- Sarkar S, Ganguly A, Sunwoo HH. Current overview of anti-tuberculosis drugs: metabolism and toxicities. Mycobact Dis. 2016;6:2.
- Gülbay BE, Gürkan ÖU, Yıldız ÖA, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006;100:1834–1842.
- Ghadyalpatil K, Prabhash K, Menon H, et al. Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. J Clin Oncol. 2010;28(15 (suppl)):6594.
- Bhatnagar V, Adelakun A, Kendall T, et al. Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis. Arch Iran Med. 2015;18:65–68.
- Sorà F, De Matteis S, Di Mario A, et al. Antituberculosis therapy and imatinib for chronic myeloid leukemia. Clin Infect Dis. 2006;43:1223.
- Agaimy A, Brueckl V, Schmidt D, et al. Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinib mesylate (glivec) for metastatic gastrointestinal stromal tumor. Case Rep Oncol. 2013;6:134–142.
- Kim DJ, Jeong S, Kong SG, et al. First case report of latent tuberculosis reactivation complicating treatment with nilotinib in chronic myeloid leukemia. Blood Res. 2019;54:151–153.
- Floyd K, Glaziou P, Zumla A, et al. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018;6:299–314.
- Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol. 2004;53:102–106.